Horizon Therapeutics Plc

-0.08 (-0.09%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)19.58B
Current PE35.49
Forward PE 17.72
2yr Forward PE 14.44
See more stats
Estimates Current Quarter
Revenue$999.45 Million
Adjusted EPS$1.47
See more estimates
10-Day MA$91.39
50-Day MA$102.39
200-Day MA$101.50
See more pivots

Horizon Therapeutics Plc Stock, NASDAQ:HZNP

Connaught House, 1 Burlington Road, Dublin, Dublin 4
United States of America
Phone: +353.1.772.2100
Number of Employees: 1395


Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.